CSL (CSL) Shares
CSL Limited is a global speciality biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. The company has a history dating back to 1916, when the Commonwealth Serum Laboratories were first established as an Australian government body focused on vaccine manufacture. In 1994 the Commonwealth facility was privatised as CSL Limited.
In 2000 the company doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG.
In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the second Australian public company to have reached a share price of over US Dollar 100 per share.
In 2011, the company received the Minister’s Award for Outstanding Equal Employment Opportunities Initiative for their Thinking Kids Children’s Centre.
In October 2014, Novartis announced its intention to sell its influenza vaccine business, including its development pipeline, to CSL for US Dollar 275 million, which was merged into the company’s BioCSL operation.
In November 2015, BioCSL rebranded the combined business with Novartis Influenza Vaccines as Seqirus, creating the world’s second largest influenza vaccine company.
OVERVIEW OF CSL
CSL oversees a global portfolio, with operations in over 35 countries, employing over 25 000 people around the world and 1 700 R&D employees. The company’s two primary businesses are CSL Behring and Seqirus.
CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. These treatments offer promise for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory; and transplant therapeutic areas. CSL Behring drives more than 85% of overall company revenue with substantial markets in Asia Pacific, Europe and North America.
Seqirus was established on 31 July 2015, following CSL’s acquisition of the Novartis influenza vaccines business, and subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally, and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the United States (US), the United Kingdom (UK) and Australia and utilises both egg-based and cell-based manufacturing technologies as well as a proprietary adjuvant.
It has leading research and development (R&D) capabilities, a broad and differentiated product portfolio and commercial operations in more than 20 countries.
VISION & VALUES OF CSL
CSL is dedicated to saving lives and improving the quality of life for people with rare and serious conditions, CSL Limited’s values are centred on community development. In seeking to achieve its community objectives, the company seeks opportunities that utilize its unique capabilities and involve its employees and other stakeholders.
The company provides monetary or product donations, sponsorships, research and education grants and scholarships, as well as in-kind support to worthy and credible non-profit organizations. The company enters into strategic partnerships with these organizations where this will enhance the overall effort. The company also matches and supports certain contributions made by its employees to their local communities.
MARKET PERFORMANCE OF CSL
CSL Limited trades on the Australian Securities Exchange (ASX), where investors can buy shares under the stock symbol -CSL. Data from the company’s 2019 financial analysis shows A strong year for the company, with revenue up 11% and reported net profit after tax of USUS Dollar 1 919 million, up 17% at constant currency.
The company continued strong growth in its core immunoglobulin and albumin therapies, with Privigen sales up 23%, Haegarda sales grew by 61%, and Idelvion sales up 40%. The company announced an interim unfranked dividend of USUS Dollar 0.85 per share, a final unfranked dividend of USUS Dollar 1.00 per share, resulting in total ordinary dividends for 2019 of USUS Dollar 1.85 per share.
The company’s stellar performance has delivered flourishing returns for investors who choose to buy shares.
Buy CSL stocks / shares – A Step by Step Guide how to Buy / Purchase CSL Stocks or Shares online.
Before buying any stock or share one has to consider a few factors.
STEP 1: PROPER RESEARCH IS ESSENTIAL
Upon deciding you want to buy CSL Stocks / Shares, it is critical for the serious investor to do proper research into the said company. Its values should align with those of the investor’s current portfolio. An investor needs to familiarise himself with the basics and history of the company, as well as its leadership and performance in the market. Its company reports should also be scrutinized.
Consultation with a brokerage firm can also assist in determining whether investing in a specific company will complement the investor’s current portfolio. The investment “risk ladder”, which identifies asset classes based on their relative riskiness, is another useful tool when determining which company’s stock / share is the best to buy.
STEP 2: CALCULATE THE AMOUNT OF INVESTMENT IN CSL STOCKS / SHARES
It is important for an investor to monitor his total investment in stock in order to keep his portfolio aligned to his investment strategy. The overall value of his holdings will change with the fluctuation in stock prices, which can throw his portfolio off balance. To determine the amount to invest, multiply the number of shares of each stock by its current market price to determine the total investment in that specific stock. For example, if you own 100 shares of a US Dollar 5 stock, multiply 100 by US Dollar 5 to get US Dollar 500.
STEP 3: DECIDE ON THE STOCK / SHARE ORDER TYPE
Investors can choose from a market order, a limit order, a stop order (also referred to as a stop-loss order) or a buy/sell stop order. It is important to familiarise yourself with each type’s pros and cons before deciding which one will suit your current stock profile best. An investor should be guided in this choice by his investment objective.
STEP 4: OPEN A BROKERAGE ACCOUNT
A brokerage account – also known as taxable investment account – is similar to a retirement account, but more flexible. Where a retirement account has limitations on the amount of money that can be contributed annually, and restrictions on when funds can be withdrawn, a brokerage account is more flexible. The latter has no income or contribution limit and the investor can withdraw his money at any given time. This flexibility, together with its potential investment gains, makes a brokerage account more attractive to serious investors. Brokerage accounts are ideal for goals or savings that are further than five years away, but closer than retirement. It can also supplement an investor’s emergency savings.
STEP 5: COMMIT AND PURCHASE CSL STOCKS / SHARES
Lastly, commit to the stock. Pro Tip: Monitor the value of your stock to ensure you have a growing stock value and dividend pay-out. Regularly check the share price online to ensure your investment delivers a positive return on investment. You are now a proud owner of CSL stocks / shares.
5 Questions to ask yourself before purchasing any stocks or shares.
- Is it the best time to buy this stock / share?
- Should I buy CSL stocks / shares in the current economic climate?
- Can I afford to buy this stock / share?
- What is the forecast of the stock / share growth?
- What is the current price per earning ration on the stock / share?